Pfau A, Stolz W, Karrer S, Szeimies R M, Landthaler M
Dermatologische Klinik und Poliklinik, Universität Regensburg.
Hautarzt. 1998 Mar;49(3):216-8. doi: 10.1007/s001050050730.
Several reports more than ten years ago provided evidence that allopurinol may be effective for cutaneous sarcoidosis. We therefore treated two patients with histologically confirmed scar sarcoidosis and two with nodular sarcoidosis. A daily dosage of 300 mg allopurinol was given over a period of 4-7 months as single drug therapy. In both patients with scar sarcoidosis, the skin manifestations completely regressed while in the patients with nodular sarcoidosis there was significant improvement. The concomittant pulmonary involvement in two patients was unpredictable, in one patient improved while the other was deteriorated, The mode of action is still unclear but because of the positive results and the low rate of side effects, allopurinol seems a reasonable agent for treating cutaneous sarcoidosis.
十多年前的几份报告提供了证据表明，别嘌呤醇可能对皮肤结节病有效。因此，我们对两名经组织学确诊为瘢痕性结节病的患者和两名结节性结节病患者进行了治疗。作为单一药物治疗，在4 - 7个月的时间里给予每日300毫克别嘌呤醇的剂量。两名瘢痕性结节病患者的皮肤表现完全消退，而结节性结节病患者有显著改善。两名患者同时存在的肺部受累情况不可预测，一名患者病情改善，另一名患者病情恶化。作用方式仍不清楚，但由于结果积极且副作用发生率低，别嘌呤醇似乎是治疗皮肤结节病的合理药物。
